Predictive value of NLR, Fib4, and APRI in the occurrence of liver failure after hepatectomy in patients with hepatocellular carcinoma

Table 2 Comparison of clinical data between the modeling cohort with liver failure and the group without liver failure, n (%) or mean ± SD

Index		Liver failure group (n = 53)	No liver failure group (n = 101)	χ2	P value
Gender	Male	29 (54.72)	57 (56.44)	0.042	0.838
	Female	24 (45.28)	44 (43.56)
Age (yr)		52.95 ± 4.20	53.11 ± 3.76	0.241	0.810
BMI (kg/m2)		21.44 ± 2.06	21.08 ± 2.23	0.977	0.330
Smoking history	No	23 (43.40)	51 (50.50)	0.520	0.471
	Yes	30 (56.60)	50 (49.50)
Drinking history	No	26 (49.06)	53 (52.48)	0.033	0.857
	Yes	27 (50.94)	48 (47.52)
Hepatitis B	No	29 (54.72)	57 (56.44)	0.042	0.838
	Yes	24 (45.28)	44 (43.56)
Tumor diameter	< 5 cm	26 (49.06)	59 (58.42)	1.231	0.267
	≥ 5 cm	27 (50.94)	42 (41.58)
Liver cirrhosis	No	40 (75.47)	85 (84.16)	0.768	0.381
	Yes	13 (24.53)	16 (15.84)
Number of tumors	< 2	26 (49.06)	53 (52.48)	0.033	0.857
	≥ 2	27 (50.94)	48 (47.52)
Child-Pugh classification	Grade A	4 (7.55)	86 (85.15)	102.766	0.000
	Grade B	16 (30.19)	15 (14.85)
	Grade C	33 (62.26)	0 (0.00)
Surgical site	Left half liver	4 (7.55)	83 (82.18)	88.726	0.000
	Right half liver	18 (33.96)	15 (14.85)
	Bilateral hemiliver	31 (58.49)	3 (2.97)
AFP	< 400 μg/L	26 (49.06)	59 (58.42)	1.231	0.267
	≥ 400 μg/L	27 (50.94)	42 (41.58)
NLR		8.31 ± 2.52	3.22 ± 1.57	15.406	0.000
Fib4		12.41 ± 4.59	6.45 ± 1.73	11.600	0.000
APRI		0.79 ± 0.25	0.32 ± 0.19	13.044	0.000

AFP: Alpha-fetoprotein; BMI: Body mass index; NLR: Neutrophil-lymphocyte ratio; Fib4: Fibrosis index based on four factors; APRI: Aspartate aminotransferase-to-platelet ratio index.